I do not want to be a broken record but we remain in a market driven by macro and not individual stock fundamentals. The one change so far this week (for the better) is that it is driving a broad bounce back in the sector. Whether this ends up marking a bottom or is simply […]
April 22nd Biotech Update
A fun fact, the 13% decline in the XBI was the 12th worst 30 performance in the 18 year history of the index. I guess that is not really a “fun” fact but it highlights just how difficult the past month has been. It is very difficult to be trader or investor in the sector […]
April 19th Biotech Update
Well, I wish something would change but we are back in the rut that was most of later year. To be fair, we did eventually break out of that rut but I will continue to be a repeating record. We need rates to break lower. I think things are getting stretched to the downside (in […]
April 17th Biotech Update
We still wait on the Middle East to see if we need to add another layer of macro worry to the markets. The longer we go on the more likely tension settle but it still seems to rest on the scale of the Israeli response and whether it compels Iran to respond. A tit-for-tat spiral […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
